TruScreen announced results from its first cervical cancer screening trial in India confirm that the TruScreen device is an effective, viable and non-invasive method of detecting cervical intra-epithelial neoplasia (CIN). The trial, conducted by the All India Institute of Medical Sciences (AIIMS) in New Delhi and the town of Ballabgarh over the period January 2018 to February 2019, screened 645 women for cervical cancer. All women in the trial underwent screening for CIN, using TruScreen's opto-electrical device and a Pap test. The sensitivity of the TruScreen device to detect CIN was 81.82% compared to 72.73% by the Pap test. The specificity of the TruScreen device was 82.87% compared to 79.81% by the Pap test. Sensitivity and specificity are measures of a screening test's ability to correctly identify disease. A high sensitivity results in fewer false negatives, and a high specificity results in fewer false positives in the screening process. The TruScreen device's ability to provide test results in real time without the need to access pathology infrastructure is its distinguishing feature. In comparison, collected tissue samples from a Pap test must be processed at a pathology laboratory, where the typical turnaround time is two to six weeks. Faster test results enable patients to access follow-up reviews for medical treatment more quickly.